{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:32:31Z","timestamp":1772263951693,"version":"3.50.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC111-2314-B-039-062-MY3 NSTC111-2320-B-039-011 NSTC110-2314-B-039-046 NSTC111-2622-B-039-004"],"award-info":[{"award-number":["NSTC111-2314-B-039-062-MY3 NSTC111-2320-B-039-011 NSTC110-2314-B-039-046 NSTC111-2622-B-039-004"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX111-11110BI"],"award-info":[{"award-number":["NHRI-EX111-11110BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["CMU109-MF-26 DMR-111-118 DMR-110-025 DMR-111-204"],"award-info":[{"award-number":["CMU109-MF-26 DMR-111-118 DMR-110-025 DMR-111-204"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019124","name":"Asia University Hospital","doi-asserted-by":"publisher","award":["AUH-11151021"],"award-info":[{"award-number":["AUH-11151021"]}],"id":[{"id":"10.13039\/100019124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Small molecule compounds targeting multiple kinases involved in neoangiogenesis have shown survival benefits in patients with unresectable hepatocellular carcinoma (HCC). Nonetheless, despite the beneficial effects of multikinase inhibitors (MKIs), a lack of boosting adjuvant limits their objective response rate. Lipid conjugates have been used to improve delivery efficacy or pharmaceutical benefits for decades. However, the feasibility of utilizing lipid-drug conjugates (LDCs) in HCC regimens remains untested. In this study, oral feeding of linoleate-fluorescein isothiocyanate conjugates showed that the compound was well distributed in a spontaneous HCC mouse model. Therefore, a rationale design was developed for chemically synthesizing a linoleate-pazopanib conjugate (LAPC). The LAPC showed a significantly improved cytotoxicity compared to the parental drug pazopanib. Pazopanib\u2019s angiogenic suppressing signals were not observed in LAPC-treated HCC cells, potentially suggesting an altered mechanism of action (MOA). In an efficacy trial comparing placebo, oral pazopanib, and LAPC treatments in the hepatitis B virus transgene-related spontaneous HCC mouse model (HBVtg-HCC), the LAPC treatment demonstrated superior tumor ablating capacity in comparison to both placebo and pazopanib treatments, without any discernible systemic toxicity. The LAPC exposure is associated with an apoptosis marker (Terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]) and an enhanced ferroptosis (glutathione peroxidase 4 [GPX4]) potential in HBVtg-HCC tumors. Therefore, the LAPC showed excellent HCC ablative efficacy with altered MOA. The molecular mechanisms of the LAPC and LDCs for HCC therapeutics are of great academic interest. Further comprehensive preclinical trials (e.g., chemical-manufacture-control, toxicity, distribution, and pharmacokinetics\/pharmacodynamics) are expected.<\/jats:p>","DOI":"10.3389\/fphar.2023.1281067","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:14:08Z","timestamp":1705378448000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth"],"prefix":"10.3389","volume":"14","author":[{"given":"Ke","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cian-Ru","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ting","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Ching","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Chang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najim","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Lung","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.2174\/1381612823666171115105721","article-title":"Characterization methods for solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)","volume":"23","author":"Andonova","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ajcp\/aqab125","article-title":"Hepatocellular carcinoma","author":"Anisha","year":"2021","journal-title":"Am. J. Clin. Pathology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.currproblcancer.2019.06.005","article-title":"Contemporary management of metastatic soft tissue sarcoma","volume":"43","author":"Bui","year":"2019","journal-title":"Curr. Problems Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd3073","article-title":"Pazopanib","volume":"9","author":"Bukowski","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1756287215614236","article-title":"Pazopanib in the treatment of advanced renal cell carcinoma","volume":"8","author":"Cella","year":"2016","journal-title":"Ther. Adv. Urology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.1039\/c7cs00521k","article-title":"Self-assembling prodrugs","volume":"46","author":"Cheetham","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.colsurfb.2019.06.020","article-title":"Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer","volume":"181","author":"Cheng","year":"2019","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2020.10.001","article-title":"Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv. cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12876-022-02210-3","article-title":"Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis","volume":"22","author":"Choi","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"B14","article-title":"CLR 131 leads a new generation of lipid-based cancer drug delivery systems","volume":"21","author":"de Lartigue","year":"2020","journal-title":"OncologyLive"},{"key":"B15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/00498254.2012.734642","article-title":"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer","volume":"43","author":"Deng","year":"2013","journal-title":"Xenobiotica"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55715","DOI":"10.18632\/oncotarget.18382","article-title":"Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy","volume":"8","author":"Ding","year":"2017","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijpharm.2018.08.010","article-title":"Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery","volume":"549","author":"Du","year":"2018","journal-title":"Int. J. Pharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jconrel.2020.07.012","article-title":"Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines","volume":"326","author":"Fattahi","year":"2020","journal-title":"J. Control. Release"},{"key":"B19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1002\/fsn3.1712","article-title":"Conjugated linoleic acid loaded nanostructured lipid carrier as a potential antioxidant nanocarrier for food applications","volume":"8","author":"Hashemi","year":"2020","journal-title":"Food Sci. Nutr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejps.2017.01.012","article-title":"Nanoformulation of dual bexarotene-tailed phospholipid conjugate with high drug loading","volume":"100","author":"He","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/lt.26264","article-title":"Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study","volume":"27","author":"Iavarone","year":"2021","journal-title":"Liver Transplant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid\u2013drug conjugate for enhancing drug delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol. Pharm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jbior.2017.11.003","article-title":"PLC\u03b31: potential arbitrator of cancer progression","volume":"67","author":"Jang","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.colsurfb.2017.03.006","article-title":"Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability","volume":"154","author":"Kaithwas","year":"2017","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PloS one"},{"key":"B28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MPH.0000000000000329","article-title":"PI3King the lock: targeting the PI3K\/Akt\/mTOR pathway as a novel therapeutic strategy in neuroblastoma","volume":"37","author":"King","year":"2015","journal-title":"J. Pediatr. hematology\/oncology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4161\/cbt.6.9.4569","article-title":"Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells","volume":"6","author":"Kumar","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.3390\/v14112355","article-title":"Application and impact of antiviral therapy for patients with HBV-related hepatocellular carcinoma receiving sorafenib and lenvatinib treatment","volume":"14","author":"Lee","year":"2022","journal-title":"Viruses"},{"key":"B32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.7150\/ijbs.42962","article-title":"Phosphoinositide specific phospholipase C\u03b31 inhibition-driven autophagy caused cell death in human lung adenocarcinoma A549 cells in vivo and in vitro","volume":"16","author":"Lu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1021\/acs.nanolett.6b01632","article-title":"Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy","volume":"16","author":"Luo","year":"2016","journal-title":"Nano Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1021\/acsbiomaterials.7b00380","article-title":"In vivo fate of biomimetic mixed micelles as nanocarriers for bioavailability enhancement of lipid\u2013drug conjugates","volume":"3","author":"Ma","year":"2017","journal-title":"ACS Biomaterials Sci. Eng."},{"key":"B36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/hep.31558","article-title":"Risk prediction models for post\u2010operative mortality in patients with cirrhosis","volume":"73","author":"Mahmud","year":"2021","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"E217","DOI":"10.1073\/pnas.1313459110","article-title":"A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity","volume":"111","author":"Maksimenko","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17425247.2018.1503249","article-title":"Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs","volume":"15","author":"Managuli","year":"2018","journal-title":"Expert Opin. drug Deliv."},{"key":"B39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/med.21533","article-title":"Lipidic prodrug approach for improved oral drug delivery and therapy","volume":"39","author":"Markovic","year":"2019","journal-title":"Med. Res. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.progpolymsci.2015.07.005","article-title":"Self-assembling polymer systems for advanced treatment of cancer and inflammation","volume":"53","author":"Palao-Suay","year":"2016","journal-title":"Prog. Polym. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"360ra135","DOI":"10.1126\/scitranslmed.aaf5219","article-title":"Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases","volume":"8","author":"Rahbari","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/S1470-2045(17)30420-5","article-title":"Palliative care in Africa: a scoping review from 2005\u201316","volume":"18","author":"Rhee","year":"2017","journal-title":"Lancet Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1021\/ja909475m","article-title":"Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery","volume":"132","author":"Shen","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejpb.2018.04.003","article-title":"Pharmacokinetics of lipid-drug conjugates loaded into liposomes","volume":"128","author":"Signorell","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur. J. cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e931856","DOI":"10.12659\/MSM.931856","article-title":"Overall survival in patients with hepatocellular carcinoma treated with sorafenib: a polish experience","volume":"27","author":"Stra\u015b","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"B48","doi-asserted-by":"publisher","first-page":"601710","DOI":"10.3389\/fonc.2020.601710","article-title":"Etiology of hepatocellular carcinoma: special focus on fatty liver disease","volume":"10","author":"Suresh","year":"2020","journal-title":"Front. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/apt.17088","article-title":"Improved survival of viral hepatocellular carcinoma but not non-viral hepatocellular carcinoma from 2000 to 2020: a multi-centre cohort study of 6007 patients from high-volume academic centres in Japan","volume":"56","author":"Toyoda","year":"2022","journal-title":"Alimentary Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40265-020-01361-5","article-title":"Cabozantinib for the treatment of advanced hepatocellular carcinoma: current data and future perspectives","volume":"80","author":"Trojan","year":"2020","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3390\/pharmaceutics14081695","article-title":"Linoleic acid-based transferosomes for topical ocular delivery of cyclosporine A","volume":"14","author":"Uwaezuoke","year":"2022","journal-title":"A. Pharm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"Hepatocell. Carcinoma N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1208\/s12249-019-1293-3","article-title":"Lipid-based nanocarriers for lymphatic transportation","volume":"20","author":"Vishwakarma","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"B54","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.actbio.2020.05.026","article-title":"Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery","volume":"111","author":"Wang","year":"2020","journal-title":"Acta biomater."},{"key":"B55","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"24","author":"Wedam","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"32ra35","DOI":"10.1126\/scitranslmed.3001143","article-title":"Androgen receptor promotes hepatitis B virus\u2013induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription","volume":"2","author":"Wu","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-981-10-5765-6_2","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"1018","author":"Xie","year":"2017","journal-title":"Infect. Agents Assoc. Cancers Epidemiol. Mol. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4103\/2319-4170.131378","article-title":"Anti-cancer activities of \u03c9-6 polyunsaturated fatty acids","volume":"37","author":"Xu","year":"2014","journal-title":"Biomed. J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"E4966","DOI":"10.1073\/pnas.1603244113","article-title":"Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis","volume":"113","author":"Yang","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1021\/acs.jmedchem.8b00384","article-title":"Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously","volume":"61","author":"Zang","year":"2018","journal-title":"J. Med. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hep.21445","article-title":"Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice","volume":"45","author":"Zheng","year":"2007","journal-title":"Hepatology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"36614","DOI":"10.1038\/srep36614","article-title":"A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic","volume":"6","author":"Zhong","year":"2016","journal-title":"Sci. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2407-11-28","article-title":"Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography","volume":"11","author":"Zhu","year":"2011","journal-title":"BMC cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1281067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:14:12Z","timestamp":1705378452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1281067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":64,"alternative-id":["10.3389\/fphar.2023.1281067"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1281067","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"article-number":"1281067"}}